HYPOTHESES~Patients with chronic respiratory diseases will have a lower antibody response to SARS-CoV-2 virus after vaccination and shorter durability of the response than control subjects without chronic disorders.~Patients on corticosteroids and other immunomodulator medications for chronic medical disorders will have a lower antibody response to SARS-CoV-2 after vaccination and shorter durability of the response than subjects with chronic disorders who are not being treated with corticosteroids and immunomodulator medications.~SPECIFIC AIMS~Enroll up to 1,000 patients receiving a SARS-CoV-2 vaccination (initial or subsequent vaccinations) in an observational study to determine vaccine antibody response and durability.~Obtain blood samples to measure antibody assess the antibody, T cell and B cell responses to SARS-CoV-2 vaccination before and every 3 months for 18 months after the initial vaccination or subsequent vaccinations (boosters) .~Categorize patients by their age, gender, race, ethnicity, underlying chronic disease, disease severity, medical therapy and comorbidities.~Assess the clinical effectiveness of the vaccine to prevent COVID-19 infections.~3. Determine the clinical features and gene expression of patients who are less responsive (have lower antibody levels and shorter duration of antibody response) to SARS-CoV-2 vaccinations.~STUDY DESIGN Patient population - up to 1,000.~Consisting of patients in the following groups:~Controls - who are NOT in any of the groups listed below.~Previous COVID infection~Asthma receiving immunomodulator medications~Asthma receiving chronic oral steroids~Asthma - NOT receiving immunomodulator medications or chronic oral steroids~Chronic Obstructive Pulmonary Disease (COPD)~Rheumatoid Arthritis receiving immunomodulator medications~Rheumatoid Arthritis NOT receiving immunomodulator medications~Interstitial lung disease~Cancer patients receiving chemotherapy~Bronchiectasis~Cystic fibrosis
The investigators will assess the antibody, T cell and B cell responses to SARS-CoV-2 vaccination before and every 3 months for 18 months after the initial vaccination or subsequent vaccinations (boosters) in adults and children including patients with chronic medical conditions.